This page has beta status

CA COST Action CA16115
A European Network for Connective Tissue Calcifying Diseases

Calcification and crystal deposition into the connective tissues is an independent risk factor for cardiovascular disease, also associated to aging, several chronic metabolic diseases & tumor malignancy and in rare inherited diseases. Initially considered as a passive, unregulated and degenerative dystrophic process, there is now evidence that this process is regulated. Advances have been made in the understanding of these finely tuned biological mechanisms. However, discoveries remain to be made to provide efficient treatments to patients. Indeed, the study of these diseases is crucial for the understanding of the mechanisms of connective tissue calcification (CTC) but is hampered by the rarity of the cases and cohorts with limited access for researchers.

Advances in the diagnosis, management and treatment of inherited CTC remain also a major drawback mainly because of the lack of training among both clinicians and patients.

In view of the different actors and their common objectives, creating a network would be the opportunity to build a community bringing together for the first time not only researchers and clinicians groups but also patients and patients’ associations, public institutions and industries through meetings, training schools, short term scientific missions and the use of social media in order to provide visibility, funding and advances in health management.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Ludovic MARTIN (FR)

Vice Chair of the Action:

Dr Tamas ARANYI (HU)

Science officer of the Action:


Administrative officer of the Action:



Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF


Last updated: 18 November 2016 top of page